Pressemitteilung vom 03.09.2019 Nachricht vom 03.09.2019


Signale (in Diskussion) [September 2019]

September 2019

  • Abiraterone – ZYTIGA (CAP); Sulphonylureas: glibenclamide – AMGLIDIA (CAP), NAP; gliclazide (NAP); gliquidone (NAP); glimepiride (NAP); glimepiride, pioglitazone – TANDEMACT (CAP); gl  ipizide (NAP); tolbutamide (NAP);
  • Adalimumab – AMGEVITA (CAP); HALIMATOZ (CAP); HEFIYA (CAP); HULIO (CAP); HUMIRA (CAP); HYRIMOZ (CAP); IMRALDI (CAP)
  • Anastrozole (NAP)
  • Durvalumab – IMFINZI (CAP)
  • Golimumab – SIMPONI (CAP)
  • Ibrutinib – IMBRUVICA (CAP)
  • Ibuprofen (NAP) and fixed-dose combinations:chlorphenamine, ibuprofen, phenylephrine (NAP); dimenhydrinate, ibuprofen, caffeine (NAP); ibuprofen, ascorbic acid (NAP); ibuprofen, caffeine (NAP); ibuprofen, codeine (NAP); ibuprofen, hydrocodone (NAP); ibuprofen, paracetamol (NAP); ibuprofen, phenylephrine (NAP); ibuprofen, pseudoephedrine (NAP)
  • Immune checkpoint inhibitors:atezolizumab – TECENTRIQ (CAP); avelumab – BAVENCIO (CAP); cemiplimab – LIBTAYO (CAP); durvalumab – IMFINZI (CAP); ipilimumab – YERVOY (CAP); nivolumab – OPDIVO (CAP); pembrolizumab - KEYTRUDA (CAP)
  • Omalizumab - XOLAIR (CAP) - EMEA/H/C/000606/SDA/068
  • Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/SDA/022
  • Perampanel - FYCOMPA (CAP) - EMEA/H/C/002434/SDA/018
  • Prasugrel – EFIENT (CAP), PRASUGREL MYLAN (CAP), NAP
  • Sacubitril, valsartan – ENTRESTO (CAP); NEPARVIS (CAP)
  • Sitagliptin – JANUVIA (CAP), RISTABEN (CAP), TESAVEL (CAP), XELEVIA (CAP); NAPsitagliptin, ertugliflozin – STEGLUJAN (CAP)sitagliptin, metformin – EFFICIB (CAP); JANUMET (CAP); VELMETIA (CAP); NAP
  • Sodium-glucose co-transporter 2 (SGLT2) inhibitors:canagliflozin – INVOKANA (CAP) - EMEA/H/C/002649/SDA/018; c  anagliflozin, metformin – VOKANAMET (CAP) - EMEA/H/C/002656/SDA/016; dapagliflozin – EDISTRIDE (CAP) - EMEA/H/C/004161/SDA/014; dapagliflozin – FORXIGA (CAP) - EMEA/H/C/002322/SDA/027; dapagliflozin, metformin – EBYMECT (CAP) - EMEA/H/C/004162/SDA/013; dapagliflozin, metformin – XIGDUO (CAP) - EMEA/H/C/002672/SDA/016; empagliflozin – JARDIANCE (CAP) - EMEA/H/C/002677/SDA/017; empagliflozin, metformin – SYNJARDY (CAP) - EMEA/H/C/003770/SDA/011; empagliflozin, linagliptin – GLYXAMBI (CAP) - EMEA/H/C/003833/SDA/008; ertugliflozin – STEGLATRO (CAP) - EMEA/H/C/004315/SDA/006; ertugliflozin, metformin – SEGLUROMET (CAP) - EMEA/H/C/004314/SDA/005; e  rtugliflozin, sitagliptin - STEGLUJAN (CAP) - EMEA/H/C/004313/SDA/006; s  axagliptin, dapagliflozin - QTERN (CAP) - EMEA/H/C/004057/SDA/002
  • Teriflunomide - AUBAGIO (CAP) - EMEA/H/C/002514/SDA/007
  • Ticagrelor - BRILIQUE (CAP) - EMEA/H/C/001241/SDA/025
  • Tocilizumab - ROACTEMRA (CAP) - EMEA/H/C/000955/SDA/058
Zurück zur Übersicht

Rechtliche Hinweise

Der BPI Wirkstoff-Alert wird mit größter Sorgfalt zusammengestellt.
Der BPI e.V. haftet jedoch nicht für Unrichtigkeiten oder Unvollständigkeiten im Zusammenhang mit den bereitgestellten Inhalten. Dies gilt im Besonderen auch für eigene unternehmerische Entscheidungen, die auf Grundlage der Informationen des BPI Wirkstoff-Alerts getroffen werden.